



## Overview


Theranostec is developing precision nanomedicines that significantly improve the delivery and effectiveness of cancer therapies, with an initial focus on head and neck cancers.

## Nanoparticles to Treat Inaccessible Tumors

There are 650 K new cases of head and neck cancer worldwide every year. These cancers are difficult to treat aggressively because of their anatomic location, with tumor recurrence as one of the leading causes of death. It is difficult for surgeons to remove these tumors and the currently available chemotherapies are toxic and lack efficacy.

***Theranostec has developed a novel, nanoparticle treatment platform allowing for targeted and effective chemotherapy, that can be enhanced with phototherapy, while also lowering toxicity.***

Theranostec’s nanoparticles have a unique trigger mechanism releasing the active compound only in the presence of the tumor, dramatically reducing toxicity and widening the therapeutic window. In addition, the photoactive components can be activated by targeted laser phototherapy to amplify the therapeutic’s effectiveness and as a potential intraoperative diagnostic. This therapeutic and diagnostic combination provides more surgical accuracy, phototherapy to address surgical margins, and on-going post-surgical chemotherapy.



## Widening Therapeutic Window

### Reducing Toxicity

Therapy only releases in the presence of the tumor

Targeted action enables higher dosing and offers potential treatment for metastasized cancers **Error! Bookmark not defined.**

### Enabling Phototherapy

Amplifies effectiveness by providing diagnostic accuracy during surgery and the ability to more accurately dose post-surgery

PROGRAM	INDICATION	DISCOVERY	LEAD OPTIMIZATION	IN VIVO TESTING	PRE-IND	CLINICAL TRIALS
TheraPhD Doxorubicin/Porphyryn	HNSCC	[Progress bar]				
TheraPhD Doxorubicin/Porphyryn	TNBC	[Progress bar]				
TheraNinja-V Vincristine	Pediatric Brain Cancer	[Progress bar]				
TheraTaxelN Paclitaxel		[Progress bar]				

## Financing

We have received funding through two Phase I SBIR grants to conduct preclinical optimization and animal testing and have received compelling data on efficacy. We are now seeking \$2M funding to perform scale-up GMP production and IND-enabling pharm/tox studies for IND filing and then \$20M to complete Phase I clinical trials.

**Dr. Yunapei Li**  
Founder & CEO

**Dr. Cindy Lin**  
Founder & COO

**Dr. Aaron Lindstrom**  
Principal Scientist